HF
CARM

HRT Financial’s Carisma Therapeutics CARM Stock Holding History

HRT Financial’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,902
Closed -$15K – 2588
2024
Q4 		$15K Buy
+36,902
New +$30.4K ﹤0.01% 2244
2023
Q1 		– Sell
-1,619
Closed -$19K – 2543
2022
Q4 		$19K Buy
+1,619
New +$17K ﹤0.01% 2184
2022
Q3 		– Sell
-8,006
Closed -$129K – 2848
2022
Q2 		$129K Buy
+8,006
New +$91.6K ﹤0.01% 2374
2021
Q4 		– Sell
-35,526
Closed -$563K – 3259
2021
Q3 		$563K Buy
+35,526
New +$1.7M ﹤0.01% 1871
2021
Q2 		– Sell
-18,964
Closed -$986K – 2897
2021
Q1 		$986K Buy
+18,964
New +$895K 0.01% 1182
2020
Q2 		– Sell
-1,032
Closed -$11K – 1552
2020
Q1 		$11K Buy
+1,032
New +$16.9K ﹤0.01% 688

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $58.1B AUM 27.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HRT Financial's CARM Position: Q1 2025 in Review

HRT Financial sold out of Carisma Therapeutics (CARM) in Q1 2025, closing a stake of 36,902 shares — an estimated $15K sold.

HRT Financial first reported a position in CARM in Q1 2020 and held it in 6 quarters. The position peaked at $986K in Q1 2021. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2025.

  • HRT Financial reported no remaining Carisma Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 36,902 Carisma Therapeutics shares in Q1 2025, an estimated $15K.
  • HRT Financial first reported a position in Carisma Therapeutics in Q1 2020 and held it in 6 quarters.
  • HRT Financial's Carisma Therapeutics position peaked at $986K in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.